title: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
abstract: BAALC expression is considered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has yet to be investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients younger than 60 years of age, treated similarly on CALGB protocols. High BAALC expression was associated with FLT3-ITD (P = .04), wild-type NPM1 (P < .001), mutated CEBPA (P = .003), MLL-PTD (P = .009), absent FLT3-TKD (P = .005), and high ERG expression (P = .05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P = .04) when adjusting for ERG expression and age, and shorter survival (P = .04) when adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis of microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile.
authors: Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
authors: Christian
authors: C
authors: Langer
authors: Michael D
authors: MD
authors: Radmacher
authors: Amy S
authors: AS
authors: Ruppert
authors: Susan P
authors: SP
authors: Whitman
authors: Peter
authors: P
authors: Paschka
authors: Krzysztof
authors: K
authors: Mrózek
authors: Claudia D
authors: CD
authors: Baldus
authors: Tamara
authors: T
authors: Vukosavljevic
authors: Chang-Gong
authors: CG
authors: Liu
authors: Mary E
authors: ME
authors: Ross
authors: Bayard L
authors: BL
authors: Powell
authors: Albert
authors: A
authors: de la Chapelle
authors: Jonathan E
authors: JE
authors: Kolitz
authors: Richard A
authors: RA
authors: Larson
authors: Guido
authors: G
authors: Marcucci
authors: Clara D
authors: CD
authors: Bloomfield
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D000090243:Nucleophosmin; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: C442828:BAALC protein, human; D014408:Biomarkers, Tumor; C000716967:NPM1 protein, human; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D000090243:Nucleophosmin